Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 79

1.

Emerging drug combinations to optimize renovascular protection and blood pressure goals.

Escobar C, Echarri R, Barrios V.

Int J Nephrol Renovasc Dis. 2012;5:69-80. doi: 10.2147/IJNRD.S7048. Epub 2012 Apr 3.

2.
3.

Cardiovascular and renal protection in type 2 diabetes mellitus: the role of calcium channel blockers.

Nosadini R, Tonolo G.

J Am Soc Nephrol. 2002 Nov;13 Suppl 3:S216-23. Review.

4.

[The future of renin inhibition].

Uresin AY, Baran E.

Turk Kardiyol Dern Ars. 2009 Oct;37 Suppl 7:32-8. Turkish.

5.

What is the role of direct renin inhibitors in the treatment of the hypertensive diabetic patient?

de la Sierra A, Salazar J.

Adv Ther. 2011 Sep;28(9):716-27. doi: 10.1007/s12325-011-0049-6. Epub 2011 Jul 29. Review.

PMID:
21809181
6.

[Are all antihypertensive drugs renoprotective?].

Wolf S, Risler T.

Herz. 2004 May;29(3):248-54. Review. German.

PMID:
15167950
7.
8.

Recent changes in the landscape of combination RAS blockade.

Epstein BJ, Smith SM, Choksi R.

Expert Rev Cardiovasc Ther. 2009 Nov;7(11):1373-84. doi: 10.1586/erc.09.127. Review.

PMID:
19900020
9.

Are angiotensin-converting enzyme inhibitors the best treatment for hypertension in type 2 diabetes?

Komers R, Anderson S.

Curr Opin Nephrol Hypertens. 2000 Mar;9(2):173-9. Review.

PMID:
10757223
10.

The 2004 Canadian recommendations for the management of hypertension: Part II--Therapy.

Khan NA, McAlister FA, Campbell NR, Feldman RD, Rabkin S, Mahon J, Lewanczuk R, Zarnke KB, Hemmelgarn B, Lebel M, Levine M, Herbert C; Canadian Hypertension Education Program.

Can J Cardiol. 2004 Jan;20(1):41-54.

PMID:
14968142
11.
12.

50 years of thiazides: should thiazide diuretics be considered third-line hypertension treatment?

Brown A, Captain B.

Am J Ther. 2011 Nov;18(6):e244-54. doi: 10.1097/MJT.0b013e3181e90863. Review.

PMID:
21436766
13.

Managing hypertension using combination therapy.

Frank J.

Am Fam Physician. 2008 May 1;77(9):1279-86. Review.

14.
15.

Clinical role of direct renin inhibition in hypertension.

Taylor AA, Pool JL.

Am J Ther. 2012 May;19(3):204-10. doi: 10.1097/MJT.0b013e3182068da5.

PMID:
21317620
16.

Rationale for angiotensin II receptor blockers in patients with low-renin hypertension.

Jamerson KA.

Am J Kidney Dis. 2000 Sep;36(3 Suppl 1):S24-30. Review.

PMID:
10986156
17.

Angiotensin receptor blockers in diabetic nephropathy: renal and cardiovascular end points.

Parving HH, Andersen S, Jacobsen P, Christensen PK, Rossing K, Hovind P, Rossing P, Tarnow L.

Semin Nephrol. 2004 Mar;24(2):147-57. Review.

PMID:
15017527
18.

[Risk and prevention of diabetic nephropathy].

Ravera M, Re M, Deferrari G.

G Ital Nefrol. 2007 Sep-Oct;24 Suppl 38:13-9. Italian.

PMID:
17922442
19.

New treatment guidelines for a patient with diabetes and hypertension.

Mogensen CE.

J Hypertens Suppl. 2003 Mar;21(1):S25-30. Review.

PMID:
12769164
20.

Systematic review on urine albumin testing for early detection of diabetic complications.

Newman DJ, Mattock MB, Dawnay AB, Kerry S, McGuire A, Yaqoob M, Hitman GA, Hawke C.

Health Technol Assess. 2005 Aug;9(30):iii-vi, xiii-163. Review.

Supplemental Content

Support Center